Camrelizumab combined with transcatheter arterial chemoembolization and sorafenib or lenvatinib for unresectable hepatocellular carcinoma: A multicenter, retrospective study

Introduction and Objectives: We initiated this study to explore the efficacy of camrelizumab combined with transcatheter arterial chemoembolization (TACE) plus sorafenib or lenvatinib versus TACE plus sorafenib or Lenvatinib for unresectable hepatocellular carcinoma (HCC). Materials and Methods: Fro...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Xiumei Jiang, Pan Wang, Ke Su, Han Li, Hao Chi, Fei Wang, Yu Liu, Ke Xu
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Elsevier 2025-07-01
Ráidu:	Annals of Hepatology
Fáttát:	Camrelizumab Transcatheter arterial chemoembolization Hepatocellular carcinoma Sorafenib Lenvatinib
Liŋkkat:	http://www.sciencedirect.com/science/article/pii/S1665268124003612
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!